Ghent University Academic Bibliography

Advanced

Bresolin_2010_Gene exGene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia

Silvia Bresolin, Marco Zecca, Christian Flotho, Luca Trentin, Andrea Zangrando, Laura Sainati, Jan Stary, Barbara De Moerloose UGent, Henrik Hasle, Charlotte M Niemeyer, et al. (2010) JOURNAL OF CLINICAL ONCOLOGY. 28(11). p.1919-1927
abstract
Purpose: Juvenile myelomonocytic leukemia (JMML) is a rare early childhood myelodysplastic/myeloproliferative disorder characterized by an aggressive clinical course. Age and hemoglobin F percentage at diagnosis have been reported to predict both survival and outcome after hematopoietic stem cell transplantation (HSCT). However, no genetic markers with prognostic relevance have been identified so far. We applied gene expression based classification to JMML samples in order to identify prognostic categories related to clinical outcome. Patients and Methods: Samples of 44 patients with JMML were available for microarray gene expression analysis. A diagnostic classification (DC) model developed for leukemia and myelodysplastic syndrome classification was used to classify the specimens and identify prognostically relevant categories. Statistical analysis was performed to determine the prognostic value of the classification and the genes identifying prognostic categories were further analyzed through R software. Results: The samples could be divided into two major groups: 20 specimens were classified as acute myeloid leukemia (AML) -like and 20 samples as nonAML-like. Four patients could not be assigned to a unique class. The 10-year probability of survival after diagnosis of AML-like and nonAML-like patients was significantly different (7% v 74%; P=.0005). Similarly, the 10-year event-free survival after HSCT was 6% for AML-like and 63% for nonAML-like patients (P=.0010). Conclusion: Gene expression based classification identifies two groups of patients with JMML with distinct prognosis outperforming all known clinical parameters in terms of prognostic relevance. Gene expression based classification could thus be prospectively used to guide clinical/therapeutic decisions.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
MYELOID-LEUKEMIA, RAS MUTATIONS, MOLECULAR CLASSIFICATION, STEM-CELL TRANSPLANTATION, PEDIATRIC MYELODYSPLASTIC SYNDROMES, DISCOVERY, PROGENITORS, CHILDREN, SURVIVAL, JMML
journal title
JOURNAL OF CLINICAL ONCOLOGY
J. Clin. Oncol.
volume
28
issue
11
pages
1919 - 1927
Web of Science type
Article
Web of Science id
000276457800017
JCR category
ONCOLOGY
JCR impact factor
18.97 (2010)
JCR rank
4/181 (2010)
JCR quartile
1 (2010)
ISSN
0732-183X
DOI
10.1200/JCO.2009.24.4426
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1142627
handle
http://hdl.handle.net/1854/LU-1142627
date created
2011-02-09 08:55:31
date last changed
2016-12-19 15:46:05
@article{1142627,
  abstract     = {Purpose: Juvenile myelomonocytic leukemia (JMML) is a rare early childhood myelodysplastic/myeloproliferative disorder characterized by an aggressive clinical course. Age and hemoglobin F percentage at diagnosis have been reported to predict both survival and outcome after hematopoietic stem cell transplantation (HSCT). However, no genetic markers with prognostic relevance have been identified so far. We applied gene expression based classification to JMML samples in order to identify prognostic categories related to clinical outcome.
Patients and Methods: Samples of 44 patients with JMML were available for microarray gene expression analysis. A diagnostic classification (DC) model developed for leukemia and myelodysplastic syndrome classification was used to classify the specimens and identify prognostically relevant categories. Statistical analysis was performed to determine the prognostic value of the classification and the genes identifying prognostic categories were further analyzed through R software.
Results: The samples could be divided into two major groups: 20 specimens were classified as acute myeloid leukemia (AML) -like and 20 samples as nonAML-like. Four patients could not be assigned to a unique class. The 10-year probability of survival after diagnosis of AML-like and nonAML-like patients was significantly different (7\% v 74\%; P=.0005). Similarly, the 10-year event-free survival after HSCT was 6\% for AML-like and 63\% for nonAML-like patients (P=.0010).
Conclusion: Gene expression based classification identifies two groups of patients with JMML with distinct prognosis outperforming all known clinical parameters in terms of prognostic relevance. Gene expression based classification could thus be prospectively used to guide clinical/therapeutic decisions.},
  author       = {Bresolin, Silvia and Zecca, Marco and Flotho, Christian and Trentin, Luca and Zangrando, Andrea and Sainati, Laura and Stary, Jan and De Moerloose, Barbara and Hasle, Henrik and Niemeyer, Charlotte M and Kronnie, Geertruy Te and Locatelli, Franco and Basso, Giuseppe},
  issn         = {0732-183X},
  journal      = {JOURNAL OF CLINICAL ONCOLOGY},
  keyword      = {MYELOID-LEUKEMIA,RAS MUTATIONS,MOLECULAR CLASSIFICATION,STEM-CELL TRANSPLANTATION,PEDIATRIC MYELODYSPLASTIC SYNDROMES,DISCOVERY,PROGENITORS,CHILDREN,SURVIVAL,JMML},
  language     = {eng},
  number       = {11},
  pages        = {1919--1927},
  title        = {Bresolin\_2010\_Gene exGene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia},
  url          = {http://dx.doi.org/10.1200/JCO.2009.24.4426},
  volume       = {28},
  year         = {2010},
}

Chicago
Bresolin, Silvia, Marco Zecca, Christian Flotho, Luca Trentin, Andrea Zangrando, Laura Sainati, Jan Stary, et al. 2010. “Bresolin_2010_Gene exGene Expression-based Classification as an Independent Predictor of Clinical Outcome in Juvenile Myelomonocytic Leukemia.” Journal of Clinical Oncology 28 (11): 1919–1927.
APA
Bresolin, S., Zecca, M., Flotho, C., Trentin, L., Zangrando, A., Sainati, L., Stary, J., et al. (2010). Bresolin_2010_Gene exGene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. JOURNAL OF CLINICAL ONCOLOGY, 28(11), 1919–1927.
Vancouver
1.
Bresolin S, Zecca M, Flotho C, Trentin L, Zangrando A, Sainati L, et al. Bresolin_2010_Gene exGene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. JOURNAL OF CLINICAL ONCOLOGY. 2010;28(11):1919–27.
MLA
Bresolin, Silvia, Marco Zecca, Christian Flotho, et al. “Bresolin_2010_Gene exGene Expression-based Classification as an Independent Predictor of Clinical Outcome in Juvenile Myelomonocytic Leukemia.” JOURNAL OF CLINICAL ONCOLOGY 28.11 (2010): 1919–1927. Print.